Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 23.1
edited by manuelmenendez
on 2025/01/29 18:46
on 2025/01/29 18:46
Change comment:
There is no comment for this version
To version 4.3
edited by manuelmenendez
on 2025/01/27 22:57
on 2025/01/27 22:57
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 0 added, 1 removed)
-
Objects (1 modified, 0 added, 2 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,10 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensionaldiagnostic framework for CNS diseases//=5 += Neurodiagnoses = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 -We aim to create a structured, interpretable, and scalable diagnostic tool. 7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) 11 11 ... ... @@ -13,73 +13,15 @@ 13 13 ((( 14 14 (% class="col-xs-12 col-sm-8" %) 15 15 ((( 16 -= What is this about and whatcan I find here? =15 += What can I find here? = 17 17 18 -== **Overview** == 17 +* `/docs`: Documentation and contribution guidelines. 18 +* `/code`: Machine learning pipelines and scripts. 19 +* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports. 19 19 20 - The//TridimensionalDiagnosticFramework// redefines CNS diseasescan beclassified and diagnosed by focusingon:21 += Who has access? = 21 21 22 -* **Axis 1**: Etiology (genetic or other causes of diseases). 23 -* **Axis 2**: Molecular Markers (biomarkers). 24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 25 - 26 -[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 27 - 28 - 29 -This methodology enables: 30 - 31 -* Greater precision in diagnosis. 32 -* Integration of incomplete datasets using AI-driven probabilistic modeling. 33 -* Stratification of patients for personalized treatment. 34 - 35 -== **The case of neurodegenerative diseases** == 36 - 37 -There have been described these 3 diagnostic axes: 38 - 39 -* ((( 40 -**Axis 1: Etiology** 41 - 42 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 43 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 44 -* //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 45 -))) 46 -* ((( 47 -**Axis 2: Molecular Markers** 48 - 49 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 50 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 51 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 52 -))) 53 -* ((( 54 -**Axis 3: Neuroanatomoclinical** 55 - 56 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 57 -* //Examples//: Hippocampal atrophy correlating with memory deficits. 58 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. 59 -))) 60 - 61 -== **Applications** == 62 - 63 -This system enhances: 64 - 65 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. 66 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 67 - 68 -== Who has access? == 69 - 70 70 We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 71 - 72 -== How to Contribute == 73 - 74 -* Access the `/docs` folder for guidelines. 75 -* Use `/code` for the latest AI pipelines. 76 -* Share feedback and ideas in the wiki discussion pages. 77 - 78 -== Key Objectives == 79 - 80 -* Develop interpretable AI models for diagnosis and progression tracking. 81 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 82 -* Foster collaboration among neuroscientists, AI researchers, and clinicians. 83 83 ))) 84 84 85 85 ... ... @@ -89,14 +89,6 @@ 89 89 {{toc/}} 90 90 {{/box}} 91 91 92 -== Main contents == 93 - 94 -* `/docs`: Documentation and contribution guidelines. 95 -* `/code`: Machine learning pipelines and scripts. 96 -* `/data`: Sample datasets for testing. 97 -* `/outputs`: Generated models, visualizations, and reports. 98 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 99 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 100 -* [[to-do-list>>to-do-list]] 33 + 101 101 ))) 102 102 )))
- tridimensional.png
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.manuelmenendez - Size
-
... ... @@ -1,1 +1,0 @@ 1 -149.8 KB - Content
- Collaboratory.Apps.Collab.Code.CollabClass[0]
-
- Public
-
... ... @@ -1,1 +1,1 @@ 1 - Yes1 +No
- XWiki.XWikiRights[3]
-
- Allow/Deny
-
... ... @@ -1,1 +1,0 @@ 1 -Allow - Levels
-
... ... @@ -1,1 +1,0 @@ 1 -view - Users
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.XWikiGuest
- XWiki.XWikiRights[4]
-
- Allow/Deny
-
... ... @@ -1,1 +1,0 @@ 1 -Allow - Groups
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.XWikiAllGroup - Levels
-
... ... @@ -1,1 +1,0 @@ 1 -view